Navigation Links
Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management
Date:2/21/2012

KING OF PRUSSIA, Pa., Feb. 21, 2012 /PRNewswire/ -- Thought leaders from the medical community in Europe and the U.S. examined the pros and cons of using albumin in treating liver disease and sepsis, and in cardiac surgery, during CSL Behring's Key Issues Dialogue – "Albumin in Clinical Fluid Management."

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO )

The participants engaged in a frank and provocative exchange about the uses and effectiveness of albumin, which is manufactured from human plasma. Albumin is used to stabilize blood pressure in shock or sepsis patients who may be albumin-deficient. It is also used to treat burn patients and augment fluid replacement therapy in cardiac surgery and in certain liver disorders. The participants discussed other patient benefits of albumin, which is a natural human protein.

Mortality rate reduction

"Albumin reduced the odds of post-paracentesis circulatory dysfunction by 61 percent (in one study)," said Mauro Bernardi, M.D., University of Bologna. "Moreover, for the first time, we were also able to show that albumin reduced mortality rate by 36 percent. We do not have a crystalloid plasma expander that reduces mortality as albumin does." Dr. Bernardi said the reduction in mortality rate in this complication of liver disease is based on a meta-analysis performed by his group at the University.

Education gap

"There is a real need to educate healthcare providers about albumin because its use has changed over time," said Gary R. Haynes, M.D., Ph.D., Saint Louis University School of Medicine, when he addressed some of the current perceptions of albumin. "Even some of the literature for volume resuscitation isn't up-to-date because we have better way
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FasterCures Spotlights Addario Lung Cancer Medical Institutes Innovative Research Programs
2. Johns Hopkins Health System is 100th healthcare Provider to Integrate OnBase With Leading Electronic Medical Record System
3. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
4. The butterfly effect in nanotech medical diagnostics
5. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
6. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
7. Rap music powers rhythmic action of medical sensor
8. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
9. Survey: Small Medical Practice Confidence Index Rises in 2012
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... 2014 More than 5 million Americans ... in 3 seniors will die with Alzheimer’s or another ... figures have shocked many Americans into looking for ways ... these tragic age-related cognitive disorders. Jonathan Weisman, president of ...
(Date:1/15/2014)... 2013 was a banner year of ... They saw continued independent research led by the team ... a $1 million grant from the Susanne Marcus Collins ... a peer reviewed journal, Amy Grant highlighted Brainwave Optimization® ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Feb. 13 Crystal Research Associates, LLC,announced today ... (EIO(R)) on Bioniche Life Sciences Inc. (BNC: TSX). ... www.crystalra.com . , Bioniche ... a Canadian,biopharmaceutical company that aims to improve the ...
... Calif., Feb. 13 InterMune, Inc. (Nasdaq: ITMN ... of 3,500,000 shares of its common stock. The last ... Global Select Market on February 12, 2009 was $17.96. ... 19, 2009, subject to customary closing conditions. All of ...
... TAIAN CITY, Shandong, China, Feb. 13 /PRNewswire-Asia-FirstCall/ -- ... Biologic" or the,"Company"), one of the leading plasma-based ... today announced that one of its R&D,projects, "High-Purity ... Torch,Plan of China. , ...
Cached Biology Technology:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc. 3InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock 2China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 2China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 3
(Date:7/9/2014)... global census of Adlie penguins shows that the ... percent larger than previously estimated. Adlie penguins have ... monitor and understand the effects of climate change ... using high-resolution satellite imagery, researchers from Stony Brook ... new method that permits regular monitoring of Adlie ...
(Date:7/9/2014)... U.S. may be on the verge of an economy driven ... cleaner than coal and is undergoing a production boom. It ... but recent research is casting serious doubts over just how ... & Engineering News (C&EN), the weekly news magazine of ... a senior correspondent at C&EN, explains that when burned as ...
(Date:7/9/2014)... drug candidate developed by researchers at the ... (NCATS) and its collaborators to treat sickle ... International,s BioScience business. The drug candidate, Aes-103, ... the underlying molecular mechanism of sickle cell ... development activities required for regulatory approval and ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... Michel Boufadel has been appointed a member of a National ... Daily Recovery Capacity. The appointment is through Nov. 14, ... techniques for skimming oil off the ocean surface following spills. ... oil spills. Boufadel has been a notable voice in ...
... 27, 2013 Elsevier, a world-leading provider of scientific, ... the launch of a new open access journal ... the International Water Association (IWA). The first issue of ... better water governance and sustainable development". All articles are ...
... who carry a gene for a specific protein face a ... study published in mBio , the online open-access journal ... neoformans is the most common cause of fungal meningitis ... everyone with HIV who has a very low level of ...
Cached Biology News:NJIT professor appointed to National Research Council 2Elsevier announces the launch of a new open access journal: Water Resources and Industry 2Gene makes some HIV-infected patients more at risk for fungal disease 2Gene makes some HIV-infected patients more at risk for fungal disease 3